Broderick C. Corless

Broderick C. Corless

Auto-generated profile, based on publicly available information

Broderick C. Corless

Molecular Pharmacology Program Memorial Sloan Kettering Cancer Center 10065 New York NY USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
BCBroderick C. Corless
Broderick C. Corless
GCGregory A. Chang
Gregory A. Chang
SCSamantha Cooper
Samantha Cooper
MSMahrukh M. Syeda
Mahrukh M. Syeda
YSYongzhao Shao
Yongzhao Shao
DPDavid Polsky
David Polsky

20 February 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
GCGregory A. Chang
Gregory A. Chang
JWJennifer M. Wiggins
Jennifer M. Wiggins
BCBroderick C. Corless
Broderick C. Corless
MSMahrukh M. Syeda
Mahrukh M. Syeda
JTJyothirmayee S. Tadepalli
Jyothirmayee S. Tadepalli
DPDavid Polsky
David Polsky

28 June 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CBCHRISTOPHER Bourne
CHRISTOPHER Bourne
PWPatrick Wallisch
Patrick Wallisch
MDMegan M. Dacek
Megan M. Dacek
TGThomas Gardner
Thomas Gardner
SPStephanie Pierre
Stephanie Pierre
DSDavid A. Scheinberg
David A. Scheinberg
Genetically engineered, cytotoxic, adoptively transferred T cells localize to antigen-positive cancer cells inside patients, but tumor heterogeneity and multiple immune escape mechanisms have prevented the eradication of most solid tumor types. More effective, multifunctional engineered T cells are in development to overcome the barriers to the treatment of solid tumors, but the interactions of these highly modified cells with the host are poorly understood. We previously engineered prodrug-activating enzymatic functions into chimeric antigen receptor (CAR) T cells, endowing them with a killing mechanism orthogonal to conventional T-cell cytotoxicity. These drug-delivering cells, termed Synthetic Enzyme-Armed KillER (SEAKER) cells, demonstrated efficacy in mouse lymphoma xenograft models. However, the interactions of an immunocompromised xenograft with such complex engineered T cells are distinct from those in an immunocompetent host, precluding an understanding of how these physiologic processes may affect the therapy. Herein, we expanded the repertoire of SEAKER cells to target solid-tumor melanomas in syngeneic mouse models using specific targeting with T-cell receptor (TCR)–engineered T cells. We demonstrate that SEAKER cells localized specifically to tumors, and activated bioactive prodrugs, despite host immune responses. We additionally show that TCR-engineered SEAKER cells were efficacious in immunocompetent hosts, demonstrating that the SEAKER platform is applicable to many adoptive cell therapies.

26 November 2025
Verified
Other
Open access
PDF file
CBCHRISTOPHER Bourne
CHRISTOPHER Bourne
PWPatrick Wallisch
Patrick Wallisch
MDMegan M. Dacek
Megan M. Dacek
TGThomas Gardner
Thomas Gardner
SPStephanie Pierre
Stephanie Pierre
DSDavid A. Scheinberg
David A. Scheinberg

19 July 2023
Verified
Other
Open access
CBCHRISTOPHER Bourne
CHRISTOPHER Bourne
PWPatrick Wallisch
Patrick Wallisch
MDMegan M. Dacek
Megan M. Dacek
TGThomas Gardner
Thomas Gardner
SPStephanie Pierre
Stephanie Pierre
DSDavid A. Scheinberg
David A. Scheinberg
Genetically engineered, cytotoxic, adoptively transferred T cells localize to antigen-positive cancer cells inside patients, but tumor heterogeneity and multiple immune escape mechanisms have prevented the eradication of most solid tumor types. More effective, multifunctional engineered T cells are in development to overcome the barriers to the treatment of solid tumors, but the interactions of these highly modified cells with the host are poorly understood. We previously engineered prodrug-activating enzymatic functions into chimeric antigen receptor (CAR) T cells, endowing them with a killing mechanism orthogonal to conventional T-cell cytotoxicity. These drug-delivering cells, termed Synthetic Enzyme-Armed KillER (SEAKER) cells, demonstrated efficacy in mouse lymphoma xenograft models. However, the interactions of an immunocompromised xenograft with such complex engineered T cells are distinct from those in an immunocompetent host, precluding an understanding of how these physiologic processes may affect the therapy. Herein, we expanded the repertoire of SEAKER cells to target solid-tumor melanomas in syngeneic mouse models using specific targeting with T-cell receptor (TCR)–engineered T cells. We demonstrate that SEAKER cells localized specifically to tumors, and activated bioactive prodrugs, despite host immune responses. We additionally show that TCR-engineered SEAKER cells were efficacious in immunocompetent hosts, demonstrating that the SEAKER platform is applicable to many adoptive cell therapies.

19 July 2023
Verified
Other
Open access
PDF file
CBCHRISTOPHER Bourne
CHRISTOPHER Bourne
PWPatrick Wallisch
Patrick Wallisch
MDMegan M. Dacek
Megan M. Dacek
TGThomas Gardner
Thomas Gardner
SPStephanie Pierre
Stephanie Pierre
DSDavid A. Scheinberg
David A. Scheinberg